U.S., Aug. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07762755) titled 'Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CT' on July 29.
Brief Summary: This randomized controlled study will evaluate whether icosapent ethyl (IPE) can improve and stabilize high-risk coronary plaques in patients receiving stable low-density lipoprotein cholesterol (LDL-C)-lowering therapy. Potential participants will have coronary plaques identified by coronary computed tomography angiography (CCTA), with 30% to 70% narrowing in at least one major coronary artery and at least one high-risk plaque feature.
After baseline imaging with fluorine-18 sodium fluoride positron emission tomography/computed to...